Episode 10. Castleman Disease
from Blood Cancer Talks Hosted by Rajshekhar Chakraborty, Ashwin Kishtagari, and Edward Cliff
Excellent overview of Castleman Disease: https://ashpublications.org/blood/article/135/16/1353/452573/Overview-of-Castleman-disease International consensus guideline for treatment of Idiopathic Multicentric Castleman Disease (iMCD): https://ashpublications.org/blood/article/132/20/2115/39506/International-evidence-based-consensus-treatment Somatic alterations in Castleman Disease: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9624446/ https://www.nature.com/articles/s41375-018-0323-6 Rituximab + Liposomal Doxorubicin in HHV8-positive MCD: https://ashpublications.org/blood/article/124/24/3544/33494/Rituximab-plus-liposomal-doxorubicin-in-HIV RCT on Siltuximab for MCD: https://pubmed.ncbi.nlm.nih.gov/25042199/ Long-term data on Siltuximab in MCD: https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026(19)30257-1/fulltext
Embed this episode
What this episode covers
In this episode, we talk Castleman Disease with Dr. Aaron Goodman (Papa Heme). We dissect the clinical and pathological classification, protean clinical manifestations, and approach to management in this rare lymphoproliferative disorder.
No transcript yet.